文献
J-GLOBAL ID:202202277085214330
整理番号:22A1025364
病原性生殖系列FANCA変異再発上皮性卵巣癌に対するPARP阻害剤による臨床的利点:症例報告【JST・京大機械翻訳】
Clinical Benefit With PARP Inhibitor for Pathogenic Germline FANCA-Mutated Relapsed Epithelial Ovarian Cancer: A Case Report
著者 (7件):
Qian Bing
(1Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China)
,
Leng Wenshu
(1Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China)
,
Yan Zhengqing
(2Department of Medical Affairs, The Medical Department, 3D Medicines Inc., Shanghai, China)
,
Lu Jin
(1Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China)
,
Chen Shiqing
(2Department of Medical Affairs, The Medical Department, 3D Medicines Inc., Shanghai, China)
,
Yi Huan
(2Department of Medical Affairs, The Medical Department, 3D Medicines Inc., Shanghai, China)
,
Jiang Zhi
(1Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China)
資料名:
Frontiers in Oncology (Web)
(Frontiers in Oncology (Web))
巻:
12
ページ:
778545
発行年:
2022年
JST資料番号:
U7089A
ISSN:
2234-943X
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
スイス (CHE)
言語:
英語 (EN)